Engene Holdings WT (ENGNW)

$1.97 -0.13 (-6.19%)

Overview
Financial
Short Interest
Institutional Holdings
Dividends
Charts

Market Cap	N/A
Revenue (ttm)	0.00
Net Income (ttm)	-99.92M
EPS (ttm)	N/A
PE Ratio	N/A
Forward PE	N/A
Profit Margin	N/A
Debt to Equity Ratio	N/A

Volume	815
Avg Vol	5,100
Day's Range	N/A - N/A
Shares Out	N/A
Stochastic %K	57%
Beta	N/A
Analysts	Strong Sell
Price Target	N/A

Company Profile

enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc...

Phone: 514 332 4888

Website: www.engene.com

Address:

4868 Rue Levy, Suite 220, Montreal, Canada